Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease Journal Article

Authors: Hirsch, A.; Vander Els, N.; Straus, D. J.; Gomez, E. G.; Leung, D.; Portlock, C. S.; Yahalom, J.
Article Title: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
Abstract: Purpose: To evaluate the effect of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy alone and of ABVD with mantle or mediastinal irradiation (RT) on the pulmonary function of patients with early-stage Hodgkin's disease (HD). Patients and Methods: Between 1989 and 1993, 60 patients with clinical stage I to III HD enrolled onto randomized trials at Memorial Sloan-Kettering Cancer Center (MSKCC) underwent prospective evaluation of pulmonary function. All patients received six cycles of ABVD, and 30 patients received mantle or mediastinal RT. Pulmonary function tests (PFTs) and symptom evaluation were conducted before, during, and after completion of chemotherapy and RT, and at various intervals thereafter. The median follow-up time was 30 months. Results: During chemotherapy, symptoms of cough and dyspnea on exertion developed in 32 of 60 patients (53%) and declines in pulmonary function occurred in 22 of 60 patients (37%). Discontinuation of bleomycin was necessary in 14 of 60 patients (23%). Following chemotherapy, there was a significant decline in median forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO). In patients who received mantle or mediastinal RT, there was a further decline in FVC following radiation therapy. At the most recent follow-up evaluation, five of 29 patients (18%) who received ABVD alone and nine of 30 (30%) who received ABVD and RT reported persistent mild pulmonary symptoms (P = .36), which did not significantly affect normal daily activity. Conclusion: ABVD chemotherapy induced acute pulmonary toxicity that required bleomycin dose modification in a substantial number of patients. The addition of RT resulted in a further decrease in FVC; however, this did not significantly affect the functional status of patients.
Keywords: adolescent; adult; clinical article; treatment outcome; aged; middle aged; doxorubicin; cancer combination chemotherapy; cancer radiotherapy; cancer staging; follow up; prospective studies; dacarbazine; lung toxicity; antineoplastic combined chemotherapy protocols; vinblastine; hodgkin disease; b cell lymphoma; lung; bleomycin; forced expiratory volume; lung function test; intravenous drug administration; vital capacity; humans; human; male; female; priority journal; article
Journal Title: Journal of Clinical Oncology
Volume: 14
Issue: 4
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1996-04-01
Start Page: 1297
End Page: 1305
Language: English
PUBMED: 8648387
PROVIDER: scopus
DOI: 10.1200/JCO.1996.14.4.1297
Notes: Article -- Export Date: 22 November 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Joachim Yahalom
    394 Yahalom
  2. Carol Portlock
    178 Portlock
  3. Arica F Hirsch
    2 Hirsch
  4. Denis Heng Yan Leung
    112 Leung
  5. David J Straus
    205 Straus